{"organizations": [], "uuid": "a3ef75274d938f4078936e5071ebf7bdd44310f6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novartis-expects-cost-cuts-rising/brief-novartis-expects-cost-cuts-rising-entresto-cosentyx-sales-to-help-meet-2018-op-profit-targets-idUSFWN1RW0HD", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targets", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.011, "site_type": "news", "published": "2018-04-19T18:51:00.000+03:00", "replies_count": 0, "uuid": "a3ef75274d938f4078936e5071ebf7bdd44310f6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novartis-expects-cost-cuts-rising/brief-novartis-expects-cost-cuts-rising-entresto-cosentyx-sales-to-help-meet-2018-op-profit-targets-idUSFWN1RW0HD", "ord_in_thread": 0, "title": "BRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targets", "locations": [], "entities": {"persons": [{"name": "kyriah", "sentiment": "none"}], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "entresto", "sentiment": "negative"}, {"name": "novartis ag", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "alcon", "sentiment": "none"}, {"name": "sandoz", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Novartis AG:\n* CEO SAYS BELIEVES COSENTYX SALES FOR FULL YEAR WILL BE IN LINE WITH CONSENSUS, HAD SOME DESTOCKING BY SPECIALTY PHARMA IN Q1 BUT BELIEVES DRUG WILL OVERCOME THAT\n* CEO SAYS SANDOZ HAD A TOUGH FIRST QUARTER, STRONG PERFORMANCE OUTSIDE US BUT CONTINUED PRICE PRESSURES THERE, LOOKING FORWARD TO UPCOMING BIOSIMILARS LAUNCHES\n* CEO SAYS ALCON ON NICE GROWTH TRAJECTORY, NOVARTIS REMAINS ON COURSE FOR POTENTIAL CAPITAL MARKETS ACTION IN 2019\n* CEO SAYS CONTINUES TO LOOK FOR BOLT-ON ACQUISITIONS IN CORE THERAPEUTIC AREAS, NEW TECHNOLOGY PLATFORMS\n* CEO SAYS WILL CONTINUE TO EVALUATE ORAL SOLIDS BUSINESS AT SANDOZ IN UNITED STATES, NO DECISIONS MADE YET\n* CEO SAYS KYRIAH OFF TO A SOLID START IN PEDIATRIC ALL, EXPECTS DLBCL APPROVAL IN US, EUROPE LATER THIS YEAR, REMAINS CONFIDENT WILL BE A BLOCKBUSTER MEDICINE\n* CEO SAYS ENTRESTO SALES GROWTH, COST CUTS, CONTINUED ALCON DEVELOPMENT WILL HELP SPUR CORE OPERATING PROFIT IMPROVEMENTS IN 2018 COMPARED TO Q1\n* CEO SAYS CURRENTLY SEARCHING FOR NEW HEAD OF BUSINESS SERVICES, BUT FEELS GOOD WITH WHERE NOVARTIS IS AS A TEAM FOLLOWING JOHN TSAIâ€™S APPOINTMENT AS NEW DRUG DEVELOPMENT CHIEF, CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T18:51:00.000+03:00", "crawled": "2018-04-20T12:05:07.001+03:00", "highlightTitle": ""}